RxSight price target lowered to $6.50 from $7.50 at Jefferies
Jefferies lowered the firm's price target on RxSight to $6.50 from $7.50 and keeps a Hold rating on the shares. Q2 preliminary results missed due to competitive trialing and macro pressures, as the company expects the trailing pressures to continue and lowered guidance by about 10% for the year, or an implied roughly 1